Sarepta Therapeutic (NASDAQ: SRPT) stock fell sharply on Tuesday after the company said the FDA considers an Eteplirsen NDA "premature ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View Hot Comments

Deutsche Bank Cuts Sarepta Therapeutic (SRPT) to Hold, PT $17November 12, 2013 3:54 PM FBR Capital Slashes Sarepta (SRPT) Price Target, But Remains 49% Above Current LevelsNovember 12, 2013 2:45 PM Sarepta (SRPT) Target Cut to $45 at Wedbush, Analyst Expects Larger Eteplirsen TrialNovember 12, 2013 2:22 PM Needham & Company Downgrades Sarepta Therapeutic (SRPT) to HoldNovember 12, 2013 12:46 PM Piper Jaffray Downgrades Sarepta Therapeutic (SRPT) to UnderweightNovember 12, 2013 8:11 AM FDA Considers Sarepta's (SRPT) NDA for Eteplirsen 'Premature'November 12, 2013 7:05 AM Sarepta Therapeutics (SRPT) Posts Mixed Q3 ResultsNovember 12, 2013 7:03 AM